Population pharmacokinetics of rituximab in patients with diffuse large B‐cell lymphoma and association with clinical outcome

AIMS: Pharmacokinetic (PK) studies suggest that there is a room for improvement in clinical use of rituximab through more individualized treatment. The objective of this study was to characterize rituximab PK in 29 newly diagnosed patients with diffuse large B‐cell lymphoma treated with rituximab in...

Descripción completa

Detalles Bibliográficos
Autores principales: Rozman, Samo, Grabnar, Iztok, Novaković, Srdjan, Mrhar, Ales, Jezeršek Novaković, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Pharmacokinetic Dynamic Relationships
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510082/
https://www.ncbi.nlm.nih.gov/pubmed/28239897
http://dx.doi.org/10.1111/bcp.13271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510082/
https://www.ncbi.nlm.nih.gov/pubmed/28239897
http://dx.doi.org/10.1111/bcp.13271

Ejemplares similares